Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A pivotal trial of BTG945 (CT900)

Trial Profile

A pivotal trial of BTG945 (CT900)

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 17 Oct 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs CT 900 (Primary)
  • Indications Ovarian cancer; Solid tumours
  • Focus Registrational; Therapeutic Use
  • Sponsors Carrick Therapeutics
  • Most Recent Events

    • 17 Oct 2018 New trial record
    • 11 Oct 2018 According to a The Institute of Cancer Research media release, the trial will be led by Dr Susanna Banerjee at The Royal Marsden NHS Foundation Trust.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top